Theranostic Strategy for Alzheimer’s Disease: A Hypothetical Nanocarri er-Mediated Co-Delivery of Colchicine and 2D Nanomaterials
Abstract:
Background: Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is marked by tau hyper phosphorylation, β-amyloid accumulation, and chronic neuroinflammation. Despite decades of research, ef fective disease-modifying treatments remain elusive. There is a growing need for multi-targeted, minimally invasive therapeutic strategies that address the complex pathology of AD.
Objective: This paper presents a novel hypothesis proposing the co-delivery of colchicine—an alkaloid derived from Gloriosa superba—and 2D nanomaterials as a dual-action therapeutic system for AD. The concept in tegrates colchicine’s anti-inflammatory and microtubule-regulatory potential with the delivery efficiency and theranostic properties of 2D nanomaterials.
Method: Through a comprehensive literature review, this work synthesizes findings on colchicine's role in tau modulation and neuroinflammation, as well as recent advancements in nanomaterial-mediated drug delivery. The proposed system involves a stimuli-responsive, ligand-functionalized nanocarrier capable of crossing the blood–brain barrier, releasing colchicine at the target site, and enabling real-time diagnostic imaging.
Results (Conceptual): This hypothesis offers a multi-modal approach that could simultaneously regulate tau aggregation, suppress chronic inflammation, and allow early-stage imaging of pathological markers. While direct experimental validation is pending, existing data on colchicine microdosing and 2D nanocarrier safety provide preliminary feasibility.
Conclusion: This paper lays the foundation for an innovative Alzheimer’s therapy by combining plant-derived compounds and nanotechnology. The proposed strategy aligns with emerging trends in precision medicine and offers a blueprint for future experimental and clinical exploration.
